Company profile for Xenetic Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fu...
Xenetic Biosciences, Inc. (NASDAQ: XBIO) is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
40 Speen Street Suite 102 Framingham, MA 01701
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-inc.-announces-adjournment-of-2025-annual-meeting-1116916

ACCESSWIRE
11 Dec 2025

https://www.pharmiweb.com/press-release/2025-11-19/xenetic-biosciences-inc-extends-research-and-development-collaboration-with-institute-investigator

PHARMIWEB
19 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-13/xenetic-biosciences-inc-reports-third-quarter-2025-financial-results

PHARMIWEB
13 Nov 2025

https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-inc.-announces-pricing-of-4.5-million-underwritten-offering-of-co-1085416

ACCESSWIRE
10 Oct 2025

https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-inc.-reports-second-quarter-2025-financial-results-1060071

ACCESSWIRE
13 Aug 2025

https://www.accessnewswire.com/newsroom/en/biotechnology/xenetic-biosciences-inc.-announces-update-from-collaboration-partner-of-first-patient-1046466

ACCESSWIRE
08 Jul 2025

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty